Investor Presentaiton

Leading, Global, Non-Clinical Drug Development Partner with a Mission to Create Healthier Lives ~21,500 Global employees ~2,600 Scientific professionals with advanced degrees Global Scale >2,000 Biopharma clients ~70% Revenue from biopharma industry >150 Locations in >20 Countries Proven Results #1 Position in Research Models, Safety Assessment & Microbial Solutions Supported >80% of FDA-approved novel drugs over last five years (2018-22) 15% Revenue CAGR 18% Non-GAAP EPS CAGR (2018-2022) Charles River Laboratories (CRL) Diverse Revenue Base by Region 26% 5% $4.0B FY 2022 revenue 69% ■North America ■Europe Asia-Pacific 4

View entire presentation